Literature DB >> 7631893

Control of renal medullary blood flow by vasopressin V1 and V2 receptors.

K Nakanishi1, D L Mattson, V Gross, R J Roman, A W Cowley.   

Abstract

Experiments were performed in anesthetized renal-denervated rats to determine the contribution of renal medullary vasopressin V1 and V2 receptor stimulation in the regulation of renal medullary blood flow. Renal medullary interstitial infusion of the selective V1 agonist [Phe2,Ile3,Orn8]vasopressin (2 ng.kg-1.min-1) significantly decreased outer medullary blood flow by 15% and inner medullary blood flow by 35%, as measured with implanted optical fibers for laser-Doppler flowmetry. Medullary interstitial infusion of equimolar doses of arginine vasopressin (AVP) also decreased outer medullary blood flow by 15% but decreased inner medullary blood flow by only 17%, a decrease significantly less than that during the infusion of the V1 agonist. These results were confirmed in videomicroscopy experiments on the exposed papilla, which demonstrated that the V1 agonist and AVP decreased descending and ascending vasa recta capillary red blood cell velocity and calculated blood flow, with greater decreases during infusion of the V1 agonist. In further laser-Doppler flowmetry studies, stimulation of V2 receptors by medullary interstitial infusion of 1-desamino-8-D-arginine vasopressin (2 ng.kg-1.min-1) or AVP in rats pretreated with the vasopressin V1 receptor antagonist d(CH2)5[Tyr(Me)2,Ala-NH2]AVP increased renal medullary blood flow by 16 +/- 3 and 27 +/- 8%, respectively. The present experiments indicate that vasopressin V1 receptor stimulation serves to decrease renal medullary blood flow while V2 receptor stimulation appears to increase renal medullary blood flow; however, the net effect of AVP is to decrease renal medullary blood flow.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7631893     DOI: 10.1152/ajpregu.1995.269.1.R193

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  7 in total

1.  Divergent roles of angiotensin II upon the immediate and sustained increases of renal blood flow following unilateral nephrectomy.

Authors:  Satoshi Shimada; Chun Yang; Theresa Kurth; Allen W Cowley
Journal:  Am J Physiol Renal Physiol       Date:  2022-02-28

2.  Arginine vasopressin infusion is sufficient to model clinical features of preeclampsia in mice.

Authors:  Jeremy A Sandgren; Guorui Deng; Danny W Linggonegoro; Sabrina M Scroggins; Katherine J Perschbacher; Anand R Nair; Taryn E Nishimura; Shao Yang Zhang; Larry N Agbor; Jing Wu; Henry L Keen; Meghan C Naber; Nicole A Pearson; Kathy A Zimmerman; Robert M Weiss; Noelle C Bowdler; Yuriy M Usachev; Donna A Santillan; Matthew J Potthoff; Gary L Pierce; Katherine N Gibson-Corley; Curt D Sigmund; Mark K Santillan; Justin L Grobe
Journal:  JCI Insight       Date:  2018-10-04

3.  Medullary thick ascending limb buffer vasoconstriction of renal outer-medullary vasa recta in salt-resistant but not salt-sensitive rats.

Authors:  Paul M O'Connor; Allen W Cowley
Journal:  Hypertension       Date:  2012-08-27       Impact factor: 10.190

4.  Effects of renal perfusion pressure on renal medullary hydrogen peroxide and nitric oxide production.

Authors:  Chunhua Jin; Chunyan Hu; Aaron Polichnowski; Takefumi Mori; Meredith Skelton; Sadayoshi Ito; Allen W Cowley
Journal:  Hypertension       Date:  2009-05-11       Impact factor: 10.190

Review 5.  Arginine vasopressin receptor signaling and functional outcomes in heart failure.

Authors:  Melissa A Wasilewski; Valerie D Myers; Fabio A Recchia; Arthur M Feldman; Douglas G Tilley
Journal:  Cell Signal       Date:  2015-07-30       Impact factor: 4.315

6.  Key influence of sex on urine volume and osmolality.

Authors:  Majuran Perinpam; Erin B Ware; Jennifer A Smith; Stephen T Turner; Sharon L R Kardia; John C Lieske
Journal:  Biol Sex Differ       Date:  2016-02-09       Impact factor: 5.027

Review 7.  Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials.

Authors:  Jonathan Urbach; Steven R Goldsmith
Journal:  Ther Adv Cardiovasc Dis       Date:  2021 Jan-Dec
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.